Investigational drug · Phase 3
LP-003
Also called: Single
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Allergic Asthma, Chronic Spontaneous Urticaria (CSU), Peanut Allergies.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
8 still active
All registered trials
11
Any phase or sponsor naming "LP-003"
First trial start
2024
Jan 26, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LP-003", any sponsor or status.
Conditions studied
As listed on its trial records.
- Allergic Asthma
- Chronic Spontaneous Urticaria (CSU)
- Peanut Allergies
- Seasonal Allergic Rhinitis
- Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
- Food Allergy
- Wheat Hypersensitivity
- Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Allergic Diseases
- Chronic Spontaneous Urticaria
Approved drugs for the same conditions: Stroke prevention · Chronic hives (urticaria) · Asthma · Allergies (allergic rhinitis) · Cardiovascular and metabolic · Immunology and inflammation · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "LP-003" as an intervention, largest first.
- Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic RhinitisPivotal-lookingActive, not recruiting
Longbio PharmaIndustry
NCT07291284 · 546 participants · Start Aug 1, 2024 · Primary completion Mar 31, 2026
Drug: LP-003; Placebo · For: Seasonal Allergic Rhinitis
Sites: Beijing, China
- A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 AntihistaminesPivotal-lookingNot yet recruiting
Longbio PharmaIndustry
NCT07946913 · 514 participants (planned) · Start Dec 7, 2026 · Primary completion Mar 24, 2028
Drug: LP-003 Injection; Omalizumab · For: Chronic Spontaneous Urticaria (CSU)
Sites: Beijing, China; Shenyang, China
- Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) TreatmentPivotal-lookingCompleted
Longbio PharmaIndustry
NCT06228560 · 202 participants · Start Jan 26, 2024 · Primary completion Apr 17, 2025
Drug: LP-003; Placebo and 1 more · For: Chronic Spontaneous Urticaria
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 17 sites in all
- Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma PatientsPivotal-lookingRecruiting
Longbio PharmaIndustry
NCT07342803 · 200 participants (planned) · Start Jan 25, 2025 · Primary completion Dec 28, 2027
Drug: LP-003 Injection; Omalizumab and 1 more · For: Allergic Asthma
Sites: Shanghai, China
- Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis AdultPivotal-lookingCompleted
Longbio PharmaIndustry
NCT06046391 · 180 participants · Start Jul 6, 2023 · Primary completion Oct 19, 2023
Drug: LP-003 dose 1; LP-003 dose 2 and 1 more · For: Seasonal Allergic Rhinitis
Sites: Beijing, China; Zhengzhou, China; Changchun, China · 17 sites in all
- A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Pivotal-lookingNot yet recruiting
Longbio PharmaIndustry
NCT07313917 · 150 participants (planned) · Start Jan 20, 2026 · Primary completion Feb 28, 2027
Drug: LP-003 Injection; Placebo of LP-003 · For: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Sites: Beijing, China
Longbio Pharma (Suzhou) Co., Ltd.Industry
NCT07785063 · 80 participants (planned) · Start Dec 2026 · Primary completion May 2029
Drug: LP-003 Injection; Placebo Injection · For: Peanut Allergies
Sites: Boston, Massachusetts; Marlton, New Jersey; Philadelphia, Pennsylvania · 13 sites in all
Longbio PharmaIndustry
NCT06294288 · 60 participants · Start Jul 13, 2022 · Primary completion Mar 4, 2024
Drug: LP-003 Dose 1 (Single); LP-003 Dose 2 (Single) and 8 more · For: Chronic Spontaneous Urticaria
Sites: Shanghai, China
- A Study of Single Dose of LP-003 in Healthy Adult SubjectsActive, not recruiting
Longbio PharmaIndustry
NCT06604949 · 12 participants · Start Oct 23, 2024 · Primary completion Nov 2026
Drug: LP-003 200mg; Placebo · For: Chronic Spontaneous Urticaria
Sites: Shanghai, China
- A Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Characteristics of LP-003 Injection in Participants With Wheat AllergyNot yet recruiting
Longbio Pharma (Suzhou) Co., Ltd.Industry
NCT07816432 · 12 participants (planned) · Start Sep 4, 2026 · Primary completion Jul 16, 2027
Drug: LP-003 Injection · For: Food Allergy; Wheat Hypersensitivity
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Pressure-guided pneumatic radial compression and radial artery occlusion after transradial coronary procedures: a retrospective historical cohort study.
Hu Y, Lv C, Zhou T, et al. · Scand Cardiovasc J 2027
- Nine minutes is enough: An accelerated fMRI protocol for reliable connectivity mapping in healthy young adults.
Falkowski A, Szwed K · Dialogues Clin Neurosci 2027
- Comparative efficacy of topical garlic extract and 20% podophyllin solution in the treatment of female genital warts: a triple-blind randomized clinical trial.
Naseri M, Sarfallah Z, Saadat M, et al. · J Dermatolog Treat 2027
- Clinical Outcomes following invasive coronary angiography for patients with acute coronary syndromes pretreated with P2Y12 inhibitors and considered for urgent coronary artery bypass graft surgery.
Lim CJ, Singh M, Sammut MA, et al. · Scand Cardiovasc J 2027
- Circulatory arrest versus aortic cross-clamping in proximal thoracic aortic aneurysm repair.
Braatz E, Stenman M, Al-Mousli J, et al. · Scand Cardiovasc J 2027
- Foundation artificial intelligence models for health recognition by use of face photographs (FAHR-Face): a model development and validation study.
Haugg F, Lee G, He J, et al. · Lancet Digit Health 2027
Also in development for Allergic Asthma
- JYB1904RPT904, ozureprubartPhase 35 trials
Jemincare · Chronic Spontaneous Urticaria, Perennial Allergic Rhinitis, Immune System Diseases
- 000 MM09Phase 32 trials
Inmunotek S.L. · Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- EP-088_MM09Phase 32 trials
Inmunotek S.L. · Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma
- FB825Phase 22 trials
Oneness Biotech Co., Ltd. · Allergic Asthma, Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.